Press Release – UK: Awakn Life Sciences Bristol Clinic Receives Care Quality Commission Approval to Begin Treatments in the UK’s First Medical Psychedelic Clinic

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today that Awakn Clinics Bristol has received Care Quality Commission’s (CQC) formal approval to begin treatments.

“This is a very exciting moment for Awakn Life Sciences, but more importantly for anyone suffering from addiction or other mental health issues in the U.K.,” said Dr. Ben Sessa, Chief Medical Officer of Awakn Life Sciences. “The recognition from the CQC is a step forward in having psychedelic therapies become a part of mainstream treatments. With the Bristol clinic recognized, Awakn remains committed to having clinical operations open to the public, to help those people who need it the most.”

Awakn Clinics Bristol is the second of three Awakn clinics to be operational this year: Bristol and London in the U.K. and Oslo in Norway which was the first. Treatments at the clinic will be led by on-site psychiatrists and will treat a number of mental health disorders and addictions.

The ketamine treatments remain subject to receipt of a final schedule 2 license from the Home Office, which the Company expects to receive in the near future.

About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.

Primary Sponsor

Top Marijuana Blog